{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.6","upperLimit":"37.6","value":"35.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Duration of Response measured from the time that measurement criteria are met for CR or PR (whichever status is recorded first) until the date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since treatment started).","dispersionType":"Full Range","groups":[{"description":"Nivolumab is a human monoclonal antibody (HuMAb; immunoglobulin G4 \\[IgG4\\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.1 Binding of PD-1 to its ligands, programmed death-ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T-cell responses to both foreign antigens as well as self-antigens. Nivolumab will be delivered intravenously at a fixed dose of 240 mg on day 1 of 14 day cycles.\n\nCabiralizumab is a recombinant, humanized Immunoglobulin G4 (IgG4) monoclonal antibody that binds to human colony stimulating factor 1 receptor (CSF1R; c-fms). Cabiralizumab will be delivered intravenously at a dosage of 4 mg/kg on day 1 of 14 day cycles.","id":"OG000","title":"Nivolumab + Cabiralizumab"}],"paramType":"MEDIAN","populationDescription":"two patients responded to treatment as defined by the protocol","reportingStatus":"POSTED","timeFrame":"at time of study drug discontinuation, up to 3 years","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}